<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Next-generation personalised medicine for high-risk paediatric cancer patients e The INFORM pilot study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-07-29">29 July 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Barbara</forename><forename type="middle">C</forename><surname>Worst</surname></persName>
							<email>b.worst@dkfz-heidelberg.de</email>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Pediatric Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cornelis</forename><forename type="middle">M</forename><surname>Van Tilburg</surname></persName>
							<email>cornelis.vantilburg@nct-heidelberg.dec.m.vantilburg</email>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">NCT Trial Center</orgName>
								<orgName type="institution">National Center for Tumor Diseases</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 130/3</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Clinical Cooperation Unit Pediatric Oncology</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gnana</forename><surname>Prakash Balasubramanian</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Division of Applied Bioinformatics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 460</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Petra</forename><surname>Fiesel</surname></persName>
							<email>petra.fiesel@med.uni-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Clinical Cooperation Unit Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruth</forename><surname>Witt</surname></persName>
							<email>ruth.witt@nct-heidelberg.de</email>
							<affiliation key="aff6">
								<orgName type="department">NCT Trial Center</orgName>
								<orgName type="institution">National Center for Tumor Diseases</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 130/3</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angelika</forename><surname>Freitag</surname></persName>
							<email>angelika.freitag@nct-heidelberg.de</email>
							<affiliation key="aff6">
								<orgName type="department">NCT Trial Center</orgName>
								<orgName type="institution">National Center for Tumor Diseases</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 130/3</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Miream</forename><surname>Boudalil</surname></persName>
							<email>miream.boudalil@med.uni-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Clinical Cooperation Unit Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><surname>Previti</surname></persName>
							<email>christopher.previti@dkfz-heidelberg.de</email>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Genomics and Proteomics Core Facility</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Wolf</surname></persName>
							<email>s.wolf@dkfz-heidelberg.de</email>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Genomics and Proteomics Core Facility</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><surname>Schmidt</surname></persName>
							<email>sabine.schmidt@dkfz-heidelberg.de</email>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Genomics and Proteomics Core Facility</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sasithorn</forename><surname>Chotewutmontri</surname></persName>
							<email>s.chotewutmontri@dkfz-heidelberg.des.chotewutmontri</email>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Genomics and Proteomics Core Facility</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Melanie</forename><surname>Bewerunge-Hudler</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Genomics and Proteomics Core Facility</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Schick</surname></persName>
							<email>m.schick@dkfz-heidelberg.de</email>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Genomics and Proteomics Core Facility</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Schlesner</surname></persName>
							<email>m.schlesner@dkfz-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Division of Theoretical Bioinformatics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Hutter</surname></persName>
							<email>b.hutter@dkfz-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Division of Applied Bioinformatics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 460</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lenka</forename><surname>Taylor</surname></persName>
							<email>lenka.taylor@med.uni-heidelberg.de</email>
							<affiliation key="aff14">
								<orgName type="department">Pharmacy Department</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 670</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tobias</forename><surname>Borst</surname></persName>
							<email>tobias.borst@uk-erlangen.de</email>
							<affiliation key="aff15">
								<orgName type="department">Pharmacy Department</orgName>
								<orgName type="institution">Erlangen University Hospital</orgName>
								<address>
									<addrLine>Palmsanlage 3</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Sutter</surname></persName>
							<email>c.sutter@med.uni-heidelberg.de</email>
							<affiliation key="aff16">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 366</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><forename type="middle">R</forename><surname>Bartram</surname></persName>
							<email>cr_bartram@med.uni-heidelberg.de</email>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 366</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elke</forename><surname>Pfaff</surname></persName>
							<email>e.pfaff@dkfz-heidelberg.de</email>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Pediatric Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Clinical Cooperation Unit Pediatric Oncology</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><forename type="middle">E</forename><surname>Kulozik</surname></persName>
							<email>andreas.kulozik@med.uni-heidelberg.de</email>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arend</forename><surname>Von Stackelberg</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="institution">Charite´-Universita¨tsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roland</forename><surname>Meisel</surname></persName>
							<email>meisel@med.uni-duesseldorf.de</email>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Du¨sseldorf University Hospital</orgName>
								<address>
									<addrLine>Moorenstr. 5, Du¨sseldorf</addrLine>
									<postCode>40225</postCode>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arndt</forename><surname>Borkhardt</surname></persName>
							<email>arndt.borkhardt@med.uni-duesseldorf.de</email>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Du¨sseldorf University Hospital</orgName>
								<address>
									<addrLine>Moorenstr. 5, Du¨sseldorf</addrLine>
									<postCode>40225</postCode>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dirk</forename><surname>Reinhardt</surname></persName>
							<email>dirk.reinhardt@uk-essen.ded.reinhardt</email>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="department" key="dep2">Pediatrics III</orgName>
								<orgName type="institution">University Hospital of Essen</orgName>
								<address>
									<addrLine>Hufelandstr. 55</addrLine>
									<postCode>45147</postCode>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan-Henning</forename><surname>Klusmann</surname></persName>
							<email>klusmann.jan-henning@mh-hannover.de</email>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Department of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<addrLine>Carl-Neuberg-Str. 1</addrLine>
									<postCode>30625</postCode>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gudrun</forename><surname>Fleischhack</surname></persName>
							<email>gudrun.fleischhack@uk-essen.de</email>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="department" key="dep2">Pediatrics III</orgName>
								<orgName type="institution">University Hospital of Essen</orgName>
								<address>
									<addrLine>Hufelandstr. 55</addrLine>
									<postCode>45147</postCode>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Tippelt</surname></persName>
							<email>stephan.tippelt@uk-essen.de</email>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="department" key="dep2">Pediatrics III</orgName>
								<orgName type="institution">University Hospital of Essen</orgName>
								<address>
									<addrLine>Hufelandstr. 55</addrLine>
									<postCode>45147</postCode>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uta</forename><surname>Dirksen</surname></persName>
							<email>uta.dirksen@ukmuenster.de</email>
							<affiliation key="aff21">
								<orgName type="department">Department of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="institution">University Hospital of Mu¨nster</orgName>
								<address>
									<addrLine>Albert-Schweitzer-Campus 1, Mu¨nster</addrLine>
									<postCode>48149</postCode>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heribert</forename><surname>Ju ¨rgens S</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Department of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="institution">University Hospital of Mu¨nster</orgName>
								<address>
									<addrLine>Albert-Schweitzer-Campus 1, Mu¨nster</addrLine>
									<postCode>48149</postCode>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christof</forename><forename type="middle">M</forename><surname>Kramm</surname></persName>
							<email>christof.kramm@med.uni-goettingen.de</email>
							<affiliation key="aff22">
								<orgName type="department">Division of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="institution">University Medical Center Go¨ttingen</orgName>
								<address>
									<addrLine>Robert-Koch-Str. 40</addrLine>
									<postCode>37075</postCode>
									<settlement>Go¨ttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andre</forename><forename type="middle">O</forename><surname>Von Bueren</surname></persName>
							<email>andre.vonburen@hcuge.ch</email>
							<affiliation key="aff22">
								<orgName type="department">Division of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="institution">University Medical Center Go¨ttingen</orgName>
								<address>
									<addrLine>Robert-Koch-Str. 40</addrLine>
									<postCode>37075</postCode>
									<settlement>Go¨ttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff23">
								<orgName type="department" key="dep1">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="department" key="dep2">Division of Pediatric Hematology and Oncology</orgName>
								<orgName type="institution">University Hospital of Geneva</orgName>
								<address>
									<addrLine>Rue Gabrielle-Perret-Gentil 4</addrLine>
									<postCode>1205</postCode>
									<settlement>Geneva</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Westermann</surname></persName>
							<email>frank.westermann@dkfz-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Division of Neuroblastoma Genomics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Fischer</surname></persName>
							<email>matthias.fischer@uk-koeln.de</email>
							<affiliation key="aff25">
								<orgName type="department">Department of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="institution">University Hospital of Cologne</orgName>
								<address>
									<addrLine>Kerpener Str. 62</addrLine>
									<postCode>50937</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="department" key="dep1">Center for Molecular Medicine Cologne (CMMC)</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<addrLine>Robert-Koch-Str. 21</addrLine>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department">Max Planck Institute for Metabolism Research</orgName>
								<address>
									<addrLine>Gleueler Str. 50</addrLine>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Birgit</forename><surname>Burkhardt</surname></persName>
							<email>birgit.burkhardt@ukmuenster.de</email>
							<affiliation key="aff21">
								<orgName type="department">Department of Pediatric Hematology &amp; Oncology</orgName>
								<orgName type="institution">University Hospital of Mu¨nster</orgName>
								<address>
									<addrLine>Albert-Schweitzer-Campus 1, Mu¨nster</addrLine>
									<postCode>48149</postCode>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wilhelm</forename><surname>Wo ¨ßmann Z</surname></persName>
							<email>wilhelm.woessmann@paediat.med.uni-giessen.de</email>
							<affiliation key="aff28">
								<orgName type="department" key="dep1">Department of Pediatric Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatric Oncology</orgName>
								<orgName type="institution">University Hospital of Gießen</orgName>
								<address>
									<addrLine>Feulgenstr. 12, Klinikum Kassel, Mo¨nchebergstr. 41-43</addrLine>
									<postCode>35392, 34125</postCode>
									<settlement>Gießen, Kassel</settlement>
									<country>Germany aa, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="department">ab Pediatric Oncology Center</orgName>
								<orgName type="institution">Technische Universita¨t Mu ¨nchen</orgName>
								<address>
									<addrLine>Ko¨lner Platz 1</addrLine>
									<postCode>80804</postCode>
									<settlement>Munich</settlement>
									<country>Germany ac</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution">Klinikum Stuttgart Olgahospital</orgName>
								<address>
									<addrLine>Kriegsbergstr. 62</addrLine>
									<postCode>70174</postCode>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department">ad Swabian Children&apos;s Cancer Center</orgName>
								<orgName type="institution">Children&apos;s Hospital</orgName>
								<address>
									<addrLine>Stenglinstr. 2</addrLine>
									<postCode>86156</postCode>
									<settlement>Klinikum Augsburg, Augsburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff32">
								<orgName type="department">Department of Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="institution" key="instit1">ae Institute for Experimental Cancer Research in Pediatrics</orgName>
								<orgName type="institution" key="instit2">University Hospital Frankfurt</orgName>
								<address>
									<addrLine>Komturstr. 3a</addrLine>
									<postCode>60528</postCode>
									<settlement>Frankfurt am Main</settlement>
									<country>Germany af</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="institution">University Hospital Frankfurt</orgName>
								<address>
									<addrLine>Theodor-Stern-Kai 7</addrLine>
									<postCode>60590</postCode>
									<settlement>Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department">ag Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology</orgName>
								<address>
									<addrLine>Auerbachstr. 112</addrLine>
									<postCode>70376</postCode>
									<settlement>Stuttgart</settlement>
									<country>Germany ah</country>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Departments of Clinical Pharmacology and Pharmacy and Biochemistry</orgName>
								<orgName type="institution">University of Tu¨bingen</orgName>
								<address>
									<addrLine>Auf der Morgenstelle 8</addrLine>
									<postCode>72076</postCode>
									<settlement>Tu¨bingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff36">
								<orgName type="department" key="dep1">ai Division of Molecular Genetics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michaela</forename><surname>Nathrath</surname></persName>
							<email>michaela.nathrath@klinikum-kassel.de</email>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">S</forename><surname>Bielack Ac</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">C</forename><surname>Fru</surname></persName>
							<email>michael.fruehwald@klinikum-augsburg.de</email>
						</author>
						<author>
							<persName><forename type="first">Simone</forename><surname>Fulda</surname></persName>
							<email>simone.fulda@kgu.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Klingebiel Af</surname></persName>
							<email>thomas.klingebiel@kgu.de</email>
						</author>
						<author>
							<persName><forename type="first">Ewa</forename><surname>Koscielniak Ac</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Schwab</surname></persName>
							<email>matthias.schwab@ikp-stuttgart.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roman</forename><surname>Tremmel</surname></persName>
							<email>roman.tremmel@ikp-stuttgart.de</email>
						</author>
						<author>
							<persName><forename type="first">Pablo</forename><surname>Herna ´iz Driever</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="institution">Charite´-Universita¨tsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><forename type="middle">H</forename><surname>Schulte</surname></persName>
							<email>johannes.schulte@charite.de</email>
							<affiliation key="aff17">
								<orgName type="department">Department of Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="institution">Charite´-Universita¨tsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="department" key="dep2">Pediatrics III</orgName>
								<orgName type="institution">University Hospital of Essen</orgName>
								<address>
									<addrLine>Hufelandstr. 55</addrLine>
									<postCode>45147</postCode>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Benedikt</forename><surname>Brors</surname></persName>
							<email>b.brors@dkfz-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Division of Applied Bioinformatics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 460</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Von Deimling</surname></persName>
							<email>andreas.vondeimling@dkfz-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Clinical Cooperation Unit Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Lichter</surname></persName>
							<email>peter.lichter@dkfz-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angelika</forename><surname>Eggert</surname></persName>
							<email>angelika.eggert@charite.de</email>
							<affiliation key="aff17">
								<orgName type="department">Department of Pediatric Oncology &amp; Hematology</orgName>
								<orgName type="institution">Charite´-Universita¨tsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Capper</surname></persName>
							<email>david.capper@med.uni-heidelberg.de</email>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Clinical Cooperation Unit Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">M</forename><surname>Pfister</surname></persName>
							<email>s.pfister@dkfz.de</email>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Pediatric Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">T W</forename><surname>Jones</surname></persName>
							<email>david.jones@dkfz.de</email>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Pediatric Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olaf</forename><surname>Witt</surname></persName>
							<email>o.witt@dkfz.de</email>
							<affiliation key="aff4">
								<orgName type="department">Department of Pediatric Oncology, Hematology &amp; Immunology</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 430</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Clinical Cooperation Unit Pediatric Oncology</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">Division of Pediatric Neurooncology (B062)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">Division of Pediatric Neurooncology (B062)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Clinical Cooperation Unit Pediatric Oncology (G340)</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 280</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Next-generation personalised medicine for high-risk paediatric cancer patients e The INFORM pilot study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-07-29">29 July 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">4E2E304A873947F2CA983CE22ADD6DF6</idno>
					<idno type="DOI">10.1016/j.ejca.2016.06.009</idno>
					<note type="submission">Received 2 June 2016; accepted 7 June 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:13+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Personalised medicine</term>
					<term>Oncology</term>
					<term>Paediatrics</term>
					<term>Precision medicine</term>
					<term>Molecular targeted therapy</term>
					<term>Deep sequencing</term>
					<term>Cancer</term>
					<term>Sarcoma</term>
					<term>Brain</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis.</s><s>In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting.</s><s>Fifty-seven patients from 20 centers were prospectively recruited.</s><s>Malignancies investigated included sarcomas (n Z 25), brain tumours (n Z 23), and others (n Z 9).</s><s>Whole-exome, low-coverage whole-genome, and RNA sequencing were complemented with methylation and expression microarray analyses.</s><s>Alterations were assessed for potential targetability according to a customised prioritisation algorithm and subsequently discussed in an interdisciplinary molecular tumour board.</s><s>Next-generation sequencing data were generated for 52 patients, with the full analysis possible in 46 of 52.</s><s>Turnaround time from sample receipt until first report averaged 28 d.</s><s>Twenty-six patients (50%) harbored a potentially druggable alteration with a prioritisation score of 'intermediate' or higher (level 4 of 7).</s><s>Common targets included receptor tyrosine kinases, phosphoinositide 3-kinaseemammalian target of rapamycin pathway, mitogen-activated protein kinase pathway, and cell cycle control.</s><s>Ten patients received a targeted therapy based on these findings, with responses observed in some previously treatment-refractory tumours.</s><s>Comparative primary relapse analysis revealed substantial tumour evolution as well as one case of unsuspected secondary malignancy, highlighting the importance of re-biopsy at relapse.</s><s>This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients.</s><s>This extended proof-of-concept, with examples of treatment consequences, expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Current treatment of childhood malignancies using modern multimodal therapies results in a 5-year overall survival (OS) of around 80% <ref type="bibr" target="#b0">[1]</ref>.</s><s>Nevertheless, certain high-risk entities remain a substantial clinical problem.</s><s>Cure rates for these tumours of less than 20% after recurrence imply an urgent need for innovative treatment strategies <ref type="bibr">[2e13]</ref>.</s><s>Whilst progress from a clinical perspective has slowed in recent years, major advances have been made in understanding cancer biology.</s><s>Multiple pipelines are now being developed to translate this knowledge and to bring next-generation sequencingbased approaches into clinical application.</s><s>Compared with adult cancers, which can be driven by, e.g.</s><s>chronic mutagenic exposure from environmental factors, most paediatric cancers carry relatively few mutations <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>This makes them attractive candidates for identifying therapeutic targets, since distinguishing driver mutations from background alterations should be comparatively easier.</s><s>Until recently, the genetic underpinnings of many paediatric cancers were largely unknown, with the exception of hereditary predisposition in 5e10% of cases <ref type="bibr" target="#b15">[16]</ref>.</s><s>Large-scale sequencing efforts in the framework of the International Cancer Genome Consortium (ICGC), the Paediatric Cancer Genome Project and other initiatives (https://icgc.org;</s><s>http://explore.pediatric</s><s>cancergenomeproject.org) <ref type="bibr">[17e19]</ref> have yielded a plethora of potential new therapeutic options.</s><s>Inspired by these opportunities, 11 study groups of the Society for Pediatric Oncology and Hematology (GPOH) as well as the German Cancer Consortium (DKTK) established the Individualized Therapy for Relapsed Malignancies in Childhood (INFORM) project to enable access to cutting-edge molecular diagnostics for high-risk paediatric oncology patients across Germany.</s></p><p><s>The comprehensive analysis conducted within this setting provides a molecular profile of each individual tumour, which is assessed for clinical relevance by an expert panel.</s><s>The whole process from sample delivery to molecular target report is intended to take less than 4 weeks.</s></p><p><s>We enrolled 57 patients in a pilot study in order to identify and overcome challenges of such an approach.</s><s>The goals were to (i) Establish logistics for real-time molecular analysis and target identification and (ii) assess relapsed high-risk paediatric malignancies with respect to patterns of potential drug targets.</s><s>Thus, we aimed to provide the basis for future biomarker-driven, cross-entity trials.</s></p><p><s>In addition to demonstrating the feasibility of the program as a whole, this pilot project provided new biological information and produced results which could be immediately translated into therapeutic application in several patients.</s><s>The key findings, presented here, highlight important considerations for such enterprises in future.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Study design and participants</head><p><s>Eligible patients included children, adolescents and young adults aged 1e40 years with refractory/relapsed/ progressive oncological disease (with initial treatment according to a GPOH protocol) as well as specific primary indications.</s><s>Detailed inclusion criteria are outlined in the Supplementary Methods and Supplementary Table <ref type="table" target="#tab_4">1</ref>.</s><s>Written informed consent covering sequencing analysis of tumour and germline, exchange of clinical and molecular data between the GPOH study groups and the coordinating center in Heidelberg as well as scientific evaluation of molecular and clinical results was obtained at the local center.</s><s>Patients and parents could decide whether they wanted to be informed about cancer-related germline alterations.</s><s>Ethics committee approval for conducting the study, use of consent forms and scientific evaluation of the data were obtained from Heidelberg University Hospital's review board.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">The INFORM workflow</head><p><s>An overview of the project workflow is outlined in Fig. <ref type="figure">1</ref> and described in the Supplementary Methods.</s><s>Briefly, fresh frozen tumour material from the current disease manifestation and matching non-neoplastic material were subjected to quality control and analyte extraction prior to molecular analysis.</s><s>Tumour content was required to be &gt;40% on histological assessment.</s><s>Bioinformatic processing is outlined below and in the Supplementary data.</s><s>An expert panel prioritised</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Day 7-17</head><p><s>Median 11 days <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref> Day 0-7   potential targets for reporting to the treating physician, who could then use the information for clinical decision making on an individual basis.</s></p><p><s>For germline analysis, we closely collaborated with our local human geneticists, who were consulted whenever we detected variants in cancer predisposition genes that were not listed as a polymorphism (http://www.ncbi.nlm.nih.</s><s>gov/SNP build 135, http://www.1000genomes.org,</s><s>http://exac.broadinstitute.org/)</s><s>and were suspected to be tumour relevant (Supplementary Table <ref type="table">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Comprehensive molecular profiling</head><p><s>Paired-end libraries from tumour and germline DNA were prepared using the Agilent SureSelectXT Human V5 kit for whole-exome sequencing (WES) and, with exclusion of the enrichment step, low-coverage wholegenome sequencing (lcWGS).</s><s>These were sequenced together with a tumour complementary DNA library (from poly(A)þ RNA, using the Illumina TruSeq RNA Kit v2) on an Illumina HiSeq2500 (paired-end 100 bp, rapid mode).</s><s>Sequencing reads were mapped to the 1000 Genomes phase 2 human reference assembly (NCBI build 37.1) using BWA (version 0.6.2).</s><s>Custom pipelines developed for use within the ICGC, as described in a recent benchmarking analysis <ref type="bibr" target="#b19">[20]</ref>, were used for detection of single-nucleotide variants (SNVs) and small insertions/deletions (InDels).</s><s>Copy number variants (CNVs) were identified from lcWGS data by manual inspection.</s><s>Gene fusions were predicted from RNA sequencing using deFuse <ref type="bibr" target="#b20">[21]</ref>.</s><s>Detailed bioinformatics methods can be found in the Supplementary data.</s></p><p><s>In addition, high-quality RNAs were analysed on the Affymetrix GeneChip U133 Plus 2.0 array, allowing for cross-comparison with a much larger cohort of reference tumour data than RNAseq.</s><s>The expression data were visualised and analysed using the online 'R2' platform (http://r2.amc.nl).</s><s>For genome-wide assessment of DNA methylation, the samples were analysed using the Illumina HumanMethylation450 BeadChip according to manufacturer's instructions.</s><s>These data were used for molecular classification by comparison with an in-house reference set.</s></p><p><s>The average costs per patient for the molecular analysis were in the range of V7000, including material shipment, data processing and storage, labor and general costs.</s><s>Neither patients nor their families incurred any direct costs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Patient characteristics</head><p><s>Over a 15-month period, we received requests for 64 patients from 20 centers across Germany to participate in the INFORM pilot.</s><s>Seven patients did not fulfil the inclusion criteria.</s><s>Table <ref type="table" target="#tab_4">1</ref> summarises the 57 enrolled patients.</s><s>The average age was 13 years, with 14 young adults (&gt;18 years) included.</s><s>Sarcomas (n Z 25) and brain tumours (n Z 23) accounted for the majority of cases.</s></p><p><s>Most enrolled patients were in a progressive or relapse situation, but eight patients at primary diagnosis for whom no standard therapy was available were also included (non-resectable high-grade gliomas, n Z 4; non-resectable or metastatic sarcomas, n Z 3 and one patient with multiple myeloma).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Integrative analysis is feasible in a clinically meaningful time frame</head><p><s>After the first 6 months of accrual (at which point final inclusion criteria were defined), the median time from biopsy to material arrival in the processing laboratory (day 0) was 15 d (Table <ref type="table" target="#tab_4">1</ref>).</s><s>Timings for subsequent analyses are given in Fig. <ref type="figure">1</ref>.</s><s>Tissue was suitable for analysis (sufficient amount and tumour cell content) in 52 of 57 cases (91%).</s><s>DNA sequencing was performed for all 52 tumours, and RNA sequencing for 48 of 52.</s><s>Thus, obtained tissue was sufficient for full profiling in most cases, including from stereotactic biopsy (e.g.</s><s>diffuse intrinsic pontine glioma).</s><s>Mean on-target WES coverage was 165-fold for tumour and 117-fold for control, with WGS coverage of 3.4-fold and 2.5-fold for tumour and control, respectively.</s><s>RNA sequencing depth averaged 220 Â 10 6 reads.</s><s>In addition, we generated DNA methylation profiles of 49 tumours (86%) and gene expression array profiles for 46 cases (81%) (Supplementary Table <ref type="table">3</ref>).</s></p><p><s>Identified molecular alterations were assessed by a multidisciplinary panel with regards to biological relevance and potential druggability (i.e.</s><s>whether a drug could be mechanistically linked to the alteration in a way which provided a rationale for its use).</s><s>In parallel, we created an internal database of genes for which, to our knowledge, directly or indirectly targeting drugs are in clinical development.</s><s>This list incorporates information from drug development pipelines, clinical trials, and signaling pathways (see Supplementary Table <ref type="table">4</ref>).</s></p><p><s>Overall, the average time from tissue arrival to discussion of results in a molecular tumour board and delivery of the preliminary report to the treating center was 28 d (range 17e43 d) (Fig. <ref type="figure">1</ref>).</s><s>Except for one SNV with an allele frequency below the sensitivity of Sanger sequencing, all potentially druggable genetic alterations (i.e.</s><s>79 of 80) were verified via orthogonal methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Potentially druggable alterations are common in highrisk paediatric tumours</head><p><s>Every reported alteration was prioritised based on a 7step scale ranging from 'very high' to 'very low,' depending on the type of alteration and its entityspecific relevance (Supplementary Table <ref type="table">5</ref>).</s><s>We also reported biologically relevant but not druggable mutations (e.g.</s><s>histone mutations in high-grade glioma) with the score 'not applicable.'</s><s>The INFORM prioritisation system has recently been harmonised with other paediatric precision oncology programs across Europe.</s><s>An overview is given in Fig. <ref type="figure">2</ref>. Fig. <ref type="figure">2</ref>. INFORM target prioritisation algorithm.</s><s>Druggable and tumour biologically relevant findings were prioritised and reported according to the given scheme.</s><s>The remaining alterations were not reported back to the treating center.</s><s>INFORM, Individualized Therapy for Relapsed Malignancies in Childhood; NA, not applicable; pred., predictive; SNV, single-nucleotide variants; synth., synthetic.</s><s>'*', Included molecular alterations: SNVs, small insertions and deletions (InDel), genomic translocations (fusion genes).</s><s>'y', Included molecular alterations: focal, high-amplitude copy number variants.</s><s>'z', Genetic alterations with some modest literature evidence of possible pathway activation.</s><s>'x', Number of patients for which this was the highest score in their identified alterations (number for NA includes those patients where no target was identified).</s></p><p><s>In total, we identified 80 potentially druggable alterations in 39 of 52 tumours (75%).</s><s>Twenty-six patients (50%) had one or more alterations with priority score 'intermediate' or higher (Supplementary Fig. <ref type="figure">1</ref>).</s><s>Many well-known oncogenic pathways were affected, including receptor tyrosine kinases, the mitogen-activated protein kinase pathway, and the phosphoinositide 3-kinaseeAKTemammalian target of rapamycin pathway, as well as cell cycle control and transcriptional regulation (Fig. <ref type="figure" target="#fig_0">3</ref>).</s><s>Notably, most gene/pathway alterations were distributed across entities and not restricted to individual tumour types.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Analysis of spatio-temporal tumour evolution</head><p><s>We analysed fresh-frozen tissue from the initial diagnosis, or a subsequent relapse, from five patients (9%).</s><s>The rate of retained mutations in the later sample varied widely (0e58%; Supplementary Table <ref type="table">6</ref>).</s><s>For all pairs, the number of non-synonymous SNVs in the relapse was equal to or higher than in the initial sample (range 1xe9.75x).</s><s>In INF_37 (ependymoma), we found no overlap in mutations between the two samples (Fig. <ref type="figure" target="#fig_1">4A</ref>), and several focal chromosomal alterations were observed in the relapse but not in the treatment-naive sample (data not shown).</s><s>We additionally performed a methylation array and targeted sequencing analysis on formalin-fixed paraffin-embedded samples from primary tumours or previous/further relapses from 14 patients (25%).</s><s>Methylation profiles remained stable over time (Supplementary Fig. <ref type="figure">2</ref>), but multiple differences were observed in the CNV and SNV profiles over time (Supplementary Table <ref type="table">7</ref>).</s><s>In certain cases, these differences involved potentially druggable alterations.</s><s>The primary tumour of INF_28, for example, harbored a focal amplification of CDK4 (a target for CDK inhibition) that was lost in the relapse (Fig. <ref type="figure" target="#fig_1">4B</ref>).</s><s>In INF_51, the primary and relapse profiles were completely different, and the assumed relapse turned out to be a secondary malignancy (glioblastoma) rather than a relapse (also confirmed histologically).</s><s>A PTPRZ1:MET fusion in the glioblastoma, which was not present in the primary medulloblastoma, represented an interesting candidate for targeted therapy.</s></p><p><s>In two cases, different regions of a single tumour were biopsied and analysed.</s><s>For both pairs, we found a remarkable difference in the number of SNVs and a mutation overlap of only 28% (INF_13) or 57% (INF_33) when comparing between samples (Supplementary Table <ref type="table">8</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">Handling of tumour-relevant germline findings</head><p><s>Germline DNA of each patient was screened for damaging alterations in a predefined list of known cancer predisposition genes (Supplementary Table <ref type="table">2</ref>).</s><s>Of 52 sequenced patients, we identified two with underlying germline mutations (4%).</s><s>For both patients, this information was previously known or clinically suspected, and they had already received human genetics counselling.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">Consequences of personalised tumour profiling on clinical decision making</head><p><s>The principle aim of this study was to develop pipelines and demonstrate feasibility, rather than systematic clinical follow-up.</s><s>Some examples of impact on treatment decisions were recorded, however.</s><s>In 10 of 26 patients with an alteration scored as intermediate or higher, the treating physician decided to apply a matched targeted therapy (regularly administered for more than 4 weeks), either as monotherapy or as a combination with other targeted therapies or conventional treatments.</s><s>One patient was included in a clinical trial, with nine treated off-label.</s><s>Furthermore, five patients in our cohort showed a discrepancy between the original histological diagnosis and our molecular classification.</s><s>Supplementary Table <ref type="table">9</ref> gives an overview of the molecular data and available clinical data of all patients.</s></p><p><s>As one example, a 12-year-old boy (INF_03) was diagnosed with a non-resectable myofibroblastic sarcoma infiltrating the skull base.</s><s>Our analysis revealed a CARS:ALK fusion (Fig. <ref type="figure" target="#fig_2">5A</ref>) and elevated ALK transcription.</s><s>Although ALK translocations are known in myofibroblastic tumours <ref type="bibr" target="#b21">[22]</ref>, this particular fusion had not been detected by standard diagnostic tests.</s><s>Based on our finding, the patient was enrolled into a clinical trial of the ALK inhibitor LDK378 (NCT01742286).</s><s>The tumour shrank considerably after 6 weeks of treatment (Fig. <ref type="figure" target="#fig_2">5B</ref>), allowing for a subsequent complete resection.</s><s>The tumour relapsed locally and with pulmonary metastases 12 months later but responded again to the ALK inhibitor.</s><s>Treatment is currently ongoing, 26 months after the initial analysis.</s></p><p><s>As a second example, analysis of a radiotherapy/ temozolomide-resistant, progressive anaplastic pilocytic astrocytoma (World Health Organization [WHO] grade III) in a 6-year-old girl (INF_59) revealed a BRAF fusion, as typically found in WHO grade I pilocytic astrocytoma <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>Treatment with the MEK-inhibitor trametinib in addition to empiric backbone therapy was subsequently initiated.</s><s>The patient is currently in a stable disease situation 9 months after the start of trametinib treatment, with a revised diagnosis of low-grade  tumour with enhanced proliferative activity (supported by methylation array analysis).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>During this pilot phase, we established and streamlined the logistics and analytical pipelines required to overcome the various challenges of real-time clinical sequencing.</s><s>We, thus, demonstrated that comprehensive molecular analysis of samples from high-risk paediatric cancer patients is feasible on a national scale and can be performed within 4 weeks.</s></p><p><s>Notably, our analyses were conducted on frozen material from a biopsy of the relapsed tumour rather than archived material.</s><s>Our results support previous reports showing substantial spatiotemporal differences in the molecular profiles of multiple samples acquired from the same patient [25e27].</s><s>Relevant predictors of increased variation seemed to be a distant recurrence and a longer time interval between primary and relapse disease (possibly associated with higher exposure to different treatments in the intervening period).</s><s>This is a crucial consideration in the context of clinical translation and underlines the need for tissue analysis of the current malignancy in order to adequately characterise and treat the latest disease manifestation.</s><s>One caveat is that even a recent sample may not be representative for all areas of the tumour, especially with metastases.</s><s>The interrogation of circulating tumour cells or cell-free nucleic acids might in future be a promising approach to pick up more subclonal events and to establish a genetic follow-up to monitor tumour evolution under therapy.</s></p><p><s>Another important feature of this study is the variety of applied methods, allowing for integrative assessment of various alterations.</s><s>Besides clear driver events, we also considered variants with lower evidence (and a lower prioritisation score), such as alterations of less-studied cancer pathway members or oncogene overexpression.</s><s>This is, to our knowledge, the most comprehensive approach compared with similar ongoing projects [28e33].</s><s>The current costs for the INFORM analysis are, therefore, higher than, for example, the recently published Ped-MiOncoSeq study (w$4000) <ref type="bibr" target="#b27">[28]</ref>, although they are likely to fall to around this figure in the near future.</s><s>In any case, this represents only a fraction of the complete costs of paediatric cancer care.</s></p><p><s>Our analysis also provides the opportunity to assess inter-individual variability in drug response on a genetic level.</s><s>For several compounds, interactions with the socalled 'pharmacogenes' involved in absorption, distribution, metabolism and excretion (ADME) have been reported, and efforts are ongoing to implement this knowledge into clinical practice <ref type="bibr" target="#b35">[34,</ref><ref type="bibr" target="#b36">35]</ref>.</s><s>We are, therefore, establishing a systematic pharmacogenomic analysis to investigate and predict individual drug response and toxicity profiles.</s></p><p><s>The era of high-throughput genomic sequencing is triggering intense discussions on ethical aspects, such as germline sequencing and handling of incidental findings.</s><s>The complexity of such issues means that there is currently a lack of consistent European guidelines <ref type="bibr" target="#b37">[36]</ref>.</s><s>In INFORM, we exclusively report (in case of consent) germline mutations that are known or very likely to elevate susceptibility to cancer (Supplementary Table <ref type="table">2</ref>).</s><s>In this selected cohort, we detected underlying cancer predisposition in only two patients (4%), which is slightly lower than previously reported <ref type="bibr" target="#b15">[16]</ref>.</s></p><p><s>The outlook for paediatric precision oncology holds significant challenges, but also substantial potential.</s><s>It is clear that the current approach of off-label or compassionate use needs to be superseded.</s><s>Difficulties with accessing targeted drugs and a hesitance to use them given limited prior knowledge are hurdles to expanding a personalised treatment approach.</s><s>Further challenges include small cohorts and a lack of suitable controls, unavailability of paediatric formulations, unclear toxicities, and a lack of reliable biomarkers.</s><s>For some patients, the INFORM pilot results clearly influenced further treatment strategies, diagnosis and/or outcome, although for most the impact on clinical course was not substantial (gathering of detailed follow-up data was also not the main aim of this pilot phase).</s><s>Thus, whilst isolated individual approaches will likely not provide significant advances <ref type="bibr" target="#b38">[37]</ref>, the generation of data on druggable alterations in relapsed paediatric tumours will provide a basis for designing interventional studies to address the need for biomarker-driven, early-phase trials for high-risk paediatric cancer patients.</s><s>The fact that particular alterations were typically not restricted to individual entities supports the rationale of a crossentity approach for these prospective studies.</s><s>Although not all tumours with a specific alteration will respond identically <ref type="bibr" target="#b39">[38]</ref>, this is still a more rational way to identify biomarkers of efficacy than the traditional 'one-size-fits-all'.</s><s>To further expand our knowledge on paediatric relapsed tumour biology, and increase the patient recruitment pool, the currently ongoing INFORM registry (the follow-up to the pilot phase; https://www.dkfz.de/en/inform/)</s><s>will soon be open to several other countries.</s><s>Trials with targeted drugs are also being designed as a second phase (INFORM2 trials).</s><s>These will be focused on combination strategies since pathway redundancy, tumour evolution and molecular crosstalk make it unlikely that monotherapies will result in durable responses in advanced cancers <ref type="bibr" target="#b14">[15]</ref>.</s><s>Compound selection will be complementary to other ongoing European projects (such as the ITCC AcSe</s></p><p><s>´-eSMART initiative) in order to provide the broadest possible opportunities for paediatric cancer patients.</s><s>At a later stage, combination of targeted small molecules with, e.g.</s><s>immunotherapeutics or epigenetic modifiers will pose an extra challenge but also add additional potential.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusion</head><p><s>The INFORM project is a comprehensive nationwide approach to rapidly profile highly aggressive tumours of children and young adults.</s><s>Sample preparation, data generation and interpretation have been optimised to allow for complete analysis within 4 weeks, enabling rapid translation into clinical decision making.</s><s>In addition, the data generated give new insights into tumour evolution and possible resistance mechanisms in relapsed disease.</s><s>As a next step, access to such programs must be expanded, and biomarker-driven, cross-entity phase I/II combination trials for paediatric patients are required.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig.3.</s><s>All druggable alterations with a priority score of intermediate or more detected within the INFORM pilot cohort (n Z 52) by whole-exome, low-coverage whole-genome, RNA-sequencing and gene expression array.</s><s>ALL, acute lymphoblastic leukaemia; DSRCT, desmoplastic small round cell tumour; InDel, small insertion or deletion; RMS, rhabdomyosarcoma; SNV, singlenucleotide variants.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. Comparison of primary-relapse pairs.</s><s>(A) Overlap of single-nucleotide variants between the primary and the relapse sample of 3 representative, Individualized Therapy for Relapsed Malignancies in Childhood (INFORM) pilot patients.</s><s>(B) Copy number plot, generated from the 450K methylation array data, for the primary and relapse tumour of INFORM patient INF_28, demonstrating a loss of CDK4 amplification in the relapse.</s></p></div></figDesc><graphic coords="8,64.58,263.27,74.58,50.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5. Pilot patient INF_03 with myofibroblastic sarcoma.</s><s>(A) Schematic image of the CARS:ALK fusion.</s><s>The copy number plots of the involved chromosomes, generated by low-coverage whole-genome sequencing, indicate the genomic break points.</s><s>(B) Magnetic resonance imaging (MRI, T1 with contrast agent, coronal view) of the tumour at diagnosis (left) and after 6 weeks of ALK-inhibitor treatment.</s></p></div></figDesc><graphic coords="8,365.24,577.31,106.79,117.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Pediatric cancer patient Informed consent Clinical management (eligibility and treatment options discussed with GPOH study center) Routine biopsy: tumor tissue</head><label></label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>(frozen + FFPE)</cell><cell></cell></row><row><cell></cell><cell cols="3">+ germline control sample (e.g. blood)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Day 17-20</cell><cell>Day 20-25</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Median 3 days [0-8]</cell><cell>Median 6 days [1-14]</cell></row><row><cell cols="2">Sample preparation</cell><cell></cell><cell></cell><cell></cell></row><row><cell>•</cell><cell>Histopathological</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>evaluation for QC</cell><cell></cell><cell></cell><cell></cell></row><row><cell>•</cell><cell>DNA and RNA extraction</cell><cell>• •</cell><cell>WES</cell><cell>(up to 5 targets per patient)</cell></row><row><cell></cell><cell></cell><cell>•</cell><cell>RNA-seq.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>•</cell><cell>Expression array</cell><cell></cell></row><row><cell></cell><cell></cell><cell>•</cell><cell>Methylation array</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">• Alignment</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Day 26 Day 26-28</head><label></label><figDesc><div><p><s>Schematic overview of the INFORM workflow and timelines.</s><s>The mean time intervals are given on top of the boxes, followed by the median time needed for each step and the range with minimal and maximal values (indicated by square brackets).</s><s>CNV, copy number variants; FFPE, formalin-fixed paraffin embedded; FISH, fluorescence in situ hybridisation; GPOH, Society for Pediatric Oncology and Hematology; InDel, small insertion or deletion; INFORM, Individualized Therapy for Relapsed Malignancies in Childhood; lcWGS, lowcoverage whole-genome sequencing; QC, quality control; RNA-seq., RNA sequencing; SNV, single-nucleotide variants; WES, wholeexome sequencing.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Median 1 day [0-11]</cell></row><row><cell></cell><cell>(germline/somatic)</cell><cell></cell></row><row><cell></cell><cell>• CNV calling</cell><cell></cell></row><row><cell>lcWGS</cell><cell>• Gene fusion prediction</cell><cell></cell></row><row><cell></cell><cell>• Quantification of</cell><cell></cell></row><row><cell></cell><cell>gene expression • Methylation classifier</cell><cell>•</cell><cell>Subsequent veri-fication prior to final report (day 26-41)</cell></row><row><cell>Fig. 1.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1</head><label>1</label><figDesc><div><p><s>Characteristics of enrolled patients (n Z 57).</s></p></div></figDesc><table><row><cell cols="2">Characteristic</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">No. %</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>13</cell></row><row><cell>Range</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1e40</cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>30</cell><cell>53</cell></row><row><cell>Female</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>27</cell><cell>47</cell></row><row><cell cols="3">Diagnosis at enrolment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Ewing sarcoma</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>11</cell><cell>19</cell></row><row><cell cols="3">WHO grade III/IV glioma</cell><cell></cell><cell></cell><cell></cell><cell>11</cell><cell>19</cell></row><row><cell cols="3">Soft tissue sarcoma</cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell>12</cell></row><row><cell cols="3">Medulloblastoma</cell><cell></cell><cell></cell><cell></cell><cell>6</cell><cell>11</cell></row><row><cell cols="2">Ependymoma</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>5</cell><cell>9</cell></row><row><cell cols="2">Neuroblastoma</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4</cell><cell>7</cell></row><row><cell cols="2">Osteosarcoma</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4</cell><cell>7</cell></row><row><cell cols="4">Acute lymphoblastic leukaemia</cell><cell></cell><cell></cell><cell>1</cell><cell>2</cell></row><row><cell cols="4">Atypical teratoid rhabdoid tumour</cell><cell></cell><cell></cell><cell>1</cell><cell>2</cell></row><row><cell>Other a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell>12</cell></row><row><cell cols="3">Disease status at enrolment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Primary disease diagnosis</cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell>12</cell></row><row><cell cols="3">Progressive primary disease</cell><cell></cell><cell></cell><cell></cell><cell>8</cell><cell>14</cell></row><row><cell>Relapse</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>41</cell><cell>72</cell></row><row><cell cols="3">Secondary malignancy</cell><cell></cell><cell></cell><cell></cell><cell>1</cell><cell>2</cell></row><row><cell cols="3">Previous therapy regimen</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Polychemotherapy AE radiotherapy</cell><cell></cell><cell></cell><cell>33</cell><cell>58</cell></row><row><cell cols="7">Polychemotherapy AE radiotherapy þ targeted treatment 7</cell><cell>12</cell></row><row><cell cols="3">No previous treatment</cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell>12</cell></row><row><cell cols="2">Unknown</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10</cell><cell>18</cell></row><row><cell cols="3">Site of origin of tissue sample</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Local to primary tumour</cell><cell></cell><cell></cell><cell></cell><cell>27</cell><cell>47</cell></row><row><cell cols="2">Metastasis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>24</cell><cell>42</cell></row><row><cell cols="3">Biopsy from different sites b</cell><cell></cell><cell></cell><cell></cell><cell>2</cell><cell>4</cell></row><row><cell cols="2">Unknown</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4</cell><cell>7</cell></row><row><cell cols="6">Time between tissue sampling and start of analysis (days) c</cell><cell></cell></row><row><cell>Median</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>15</cell></row><row><cell>Range</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">0e112</cell></row><row><cell cols="5">Additional samples received of analysed patients</cell><cell></cell><cell></cell></row><row><cell cols="5">Primary tumour sample/previous relapse</cell><cell></cell><cell></cell></row><row><cell cols="3">Fresh-frozen tissue</cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>5</cell></row><row><cell cols="3">Paraffin-embedded tissue</cell><cell></cell><cell></cell><cell></cell><cell>14</cell><cell>25</cell></row><row><cell cols="3">Later relapse/progression</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Fresh-frozen tissue</cell><cell></cell><cell></cell><cell></cell><cell>2</cell><cell>4</cell></row><row><cell>Only</cell><cell>for</cell><cell>patients</cell><cell>enrolled</cell><cell>from</cell><cell>04/2014</cell><cell cols="2">onwards</cell></row><row><cell cols="3">(INF_25eINF_64).</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a Other entities: adrenal hypernephroma, anaplastic multiple myeloma, germ cell tumour, myofibroblastic sarcoma, pancreatic neuroendocrine tumour, synovial sarcoma, undifferentiated sarcoma.b</s><s>INF_14: high-grade glioma: hotspot and periphery; INF_33: neuroblastoma: primary tumour site and lymph node metastasis.</s><s>c</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">B.C. Worst et al. / European Journal of Cancer 65 (2016) 91e101</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors would like to thank the patients and their families for participating in this study as well as the contributing centers.</s><s>In addition, we thank the High-Throughput Sequencing Unit and the Microarray Unit of the DKFZ Genomics and Proteomics Core Facility and the Microarray Department of the University of Amsterdam and the University of Heidelberg Department of Neuropathology for excellent technical support.</s><s>We also gratefully acknowledge Ivo Buchhalter, Zuguang Gu, Nagarajan Paramasivam, Rolf Kabbe, Alexander Balz and Ingrid Scholz (DKFZ Division of Theoretical Bioinformatics) for bioinformatic and data management support.</s></p><p><s>The INFORM pilot phase was funded by the German Cancer Consortium (DKTK) and the Shantella foundation (Vaduz, Liechtenstein).</s><s>We acknowledge additional support from the Deutsche Krebshilfe (#108128) and ERA-Net-TRANSCAN (01KT131) for U. Dirksen; the Robert Bosch Stiftung for M. Schwab, and the German Jose Carreras Foundation (DJCLS R13/26) for A. Borkhardt.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest statement</head><p><s>It is the opinion of the corresponding authors that there are no conflicts of interest relevant for the subject matter of the current study.</s><s>A full list of all relationships is provided in the online version of the article.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix A. Supplementary data</head><p><s>Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.ejca.2016.06.009.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Childhood cancer survival in Europe 1999e2007: results of EUROCARE-5ea population-based study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Gatta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Botta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Aareleid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bielska-Lasota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Clavel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="35" to="e47" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Kempf-Bielack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Bielack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jurgens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Branscheid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Berdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">U</forename><surname>Exner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="559" to="e68" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group</title>
		<author>
			<persName><forename type="first">A</forename><surname>Von Stackelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Volzke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kuhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Seeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schrauder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Escherich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="90" to="e97" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01</title>
		<author>
			<persName><forename type="first">U</forename><surname>Creutzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Dworzak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tamminga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Abrahamsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1472" to="e1478" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups</title>
		<author>
			<persName><forename type="first">O</forename><surname>Oberlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bisogno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="2384" to="e2389" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ramaswamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Remke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bouffet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Faria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Perreault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1200" to="e1207" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A retrospective analysis of recurrent intracranial ependymoma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Antony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Olch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mccomb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krieger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1195" to="e201" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Risk of recurrence and survival after relapse in patients with Ewing sarcoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ranft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paulussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bolling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vieth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bielack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="549" to="e53" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Treatment of highgrade glioma in children and adolescents</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aguilera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Kramm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1049" to="1e58" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>London</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Castel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Monclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Ambros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Cohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="3286" to="3e92" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Outcomes of treatment of children and adolescents with recurrent non-Hodgkin&apos;s lymphoma and Hodgkin&apos;s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children&apos;s Cancer Group Study CCG-5912</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Kobrinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sposto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Delaat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Morse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2390" to="e2396" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Childhood atypical teratoid rhabdoid tumor of the central nervous system: a metaanalysis of observational studies</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">H</forename><surname>Athale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Duckworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Odame</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="651" to="e63" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bautista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Giannatale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dias-Gastellier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fahd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valteau-Couanet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Couanet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="e102" to="e110" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Mutational heterogeneity in cancer and the search for new cancer-associated genes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stojanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Polak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Kryukov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cibulskis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sivachenko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">499</biblScope>
			<biblScope unit="issue">7457</biblScope>
			<biblScope unit="page" from="214" to="e218" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Cancer genome landscapes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Vogelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Papadopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Velculescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Diaz</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Kinzler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="issue">6127</biblScope>
			<biblScope unit="page" from="1546" to="1e58" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Germline mutations in predisposition genes in pediatric cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Edmonson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Gruber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Easton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2336" to="e2346" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Future of clinical genomics in pediatric oncology</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Janeway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Place</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Kieran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1893" to="e903" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Molecular profiling of childhood cancer: biomarkers and novel therapies</title>
		<author>
			<persName><forename type="first">F</forename><surname>Saletta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wadham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Ziegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mccowage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BBA Clin</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="59" to="e77" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Translating genomic discoveries to the clinic in pediatric oncology</title>
		<author>
			<persName><forename type="first">Glade</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pediatr</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="34" to="e43" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Alioto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Buchhalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Derdak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hutter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Eldridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hovig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">10001</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mcpherson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hormozdiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zayed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Giuliany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Sun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Comput Biol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">e1001138</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Tothova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="409" to="e413" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Cin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Janzarik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="763" to="e74" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">MAPK pathway activation in pilocytic astrocytoma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gronych</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Witt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pfister</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Life Sci</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1799" to="e811" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Spatiotemporal evolution of the primary glioblastoma genome</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="318" to="e328" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Mutational dynamics between primary and relapse neuroblastomas</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Koster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Assenov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Althoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peifer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mahlow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="872" to="e877" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Divergent clonal selection dominates medulloblastoma at recurrence</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Morrissy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Garzia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Shih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zuyderduyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Skowron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">529</biblScope>
			<biblScope unit="issue">7586</biblScope>
			<biblScope unit="page" from="351" to="e357" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Integrative clinical sequencing in the management of refractory or relapsed cancer in youth</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lonigro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roychowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vats</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="913" to="e925" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Personalized oncology through integrative highthroughput sequencing: a pilot study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Roychowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Iyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lonigro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">111</biblScope>
			<biblScope unit="page" from="111" to="121" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Winquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Goss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hotte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1547" to="1e55" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Ferte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Massard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ileana</forename><forename type="middle">E</forename><surname>Hollebecque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lacroix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ammari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Interim analysis of 420 patients</title>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<date type="published" when="2014-10-01">Oct 1 2014. 19</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<idno type="DOI">10.1158/1538-7445.AM2014-CT240</idno>
		<ptr target="http://dx.doi.org/10.1158/1538-7445.AM2014-CT240.MeetingAbstract" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Personalized medicine for patients with advanced cancer in the phase I program at MD anderson: validation and landmark analyses</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Tsimberidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Wheler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Falchook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="4827" to="e4836" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Tourneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kamal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tredan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Delord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Campone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goncalves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Target Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="253" to="e65" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Omics and drug response</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">M</forename><surname>Zanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwab</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Pharmacol Toxicol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="475" to="e502" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Pharmacogenomics in the clinic</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Relling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">526</biblScope>
			<biblScope unit="issue">7573</biblScope>
			<biblScope unit="page" from="343" to="e50" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Towards a European consensus for reporting incidental findings during clinical NGS testing</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Hehir-Kwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Claustres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Hastings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Ravenswaaij-Arts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Christenhusz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Genuardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1601" to="e1606" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Tourneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Delord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Goncalves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gavoille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dubot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Isambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1324" to="e1334" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Hyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Puzanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Subbiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Faris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Chau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Blay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="726" to="e736" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
